{"type":"rich","version":"1.0","title":"The BioPharm Brief: Gene Editing, Myeloma, Neuroregeneration","description":"Today’s BioPharm Brief covers promising Phase 1 data for Eli Lilly’s gene-editing therapy VERVE-102, evolving CAR-T and bispecific competition in multiple myeloma, and new preclinical findings for a Parkinson’s disease regenerative therapy candidate.","author_name":"The BioPharm Brief","author_url":"https://audioboom.com/channels/5167274-the-biopharm-brief","provider_name":"Audioboom","provider_url":"https://audioboom.com","width":480,"height":95,"thumbnail_url":"https://audioboom.com/i/43664516/600x600/c","thumbnail_width":600,"thumbnail_height":600,"html":""}